Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of Risperidone Response in Early-Stage Schizophrenia
NCT03323437Phase 4Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2017
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of risperidone in schizophrenia, sponsored by Weill Cornell Medicine. Started Sep 2017; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03323437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03323437.